Recall rebound boosts J&J quarterly results

Share this article:

Johnson & Johnson ended the first quarter with $17.5 billion in sales, an 8.5% increase over the same period last year.

US sales were $8 billion, up just over 11% compared to the same period last year, and international sales were $9.5 billion, up just over 6%. Consumer products – which includes baby care, oral care, and OTC medications, among other categories – saw sales rise 2% over the same period last year, to $3.7 billion, up from $3.6 billion. Part of this growth comes from getting products back on shelves after a series of recalls.

Pharmaceutical sales were up around 15% in the US and 6% internationally. Notable growth spots included biologic Stelara, with sales rising 57% overall, compared to the same period last year, and 75% in the US, to $226 million, and to $120 million internationally. Sales of schizophrenia medication Invega rose 64% in the US, to $164 million for the quarter, and 98% internationally, to $120 million. Sales of prostate cancer drug Zytiga sales rose 72% overall, to $344 million, with  $161 million in US sales and $183 million internationally.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions